Insmed to Host Investor Call to Discuss Topline Results from Phase 3 ASPEN Study of Brensocatib in Patients with Bronchiectasis

Rhea-AI Summary

Insmed will host an investor call on May 28, 2024, at 8:00 am ET to discuss the topline results from the Phase 3 ASPEN study of brensocatib in patients with non-cystic fibrosis bronchiectasis. The company will release the results at 6:30 am ET, prior to the call. The ASPEN study is a global, randomized, double-blind, placebo-controlled trial evaluating the efficacy, safety, and tolerability of brensocatib. The conference call can be accessed via phone or webcast, with a replay available until June 27, 2024.

Positive

• Hosting of investor call demonstrates transparency and willingness to engage with shareholders.
• Immediate release of topline results shows confidence in the study's outcomes.
• Global, randomized, double-blind, placebo-controlled Phase 3 study increases credibility and robustness of the data.

Negative

• No specific details about the results are provided in the PR, leading to uncertainty.
• Potential negative outcomes from the Phase 3 study could impact stock performance.
• Future expenses related to ongoing or additional studies may affect financial stability.

—Conference Call to Take Place Tomorrow, Tuesday, May 28, 2024, at 8:00 am ET—

BRIDGEWATER, N.J., May 27, 2024 /PRNewswire/ -- Insmed Incorporated (Nasdaq: INSM), a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases, today announced that it will host a conference call and webcast tomorrow, Tuesday, May 28, 2024, at 8:00 am ET to discuss topline results from the ASPEN study, a global, randomized, double-blind, placebo-controlled Phase 3 study to assess the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis. The Company plans to issue a press release sharing the topline results at approximately 6:30 am ET tomorrow, prior to the start of the conference call.

Conference Call

Shareholders and other interested parties may participate in the conference call by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) and referencing access code 1245105. The call will also be webcast live on the Company's website at www.insmed.com.

A replay of the conference call will be accessible approximately one hour after its completion through June 27, 2024, by dialing (800) 770-2030 (U.S.) or (609) 800-9909 (international) and referencing access code 1245105. A webcast of the call will also be archived for 90 days under the Investor Relations section of the Company's website at www.insmed.com.

About Insmed

Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is a first-in-disease therapy approved in the United States, Europe, and Japan to treat a chronic, debilitating lung disease. The Company is progressing a robust pipeline of investigational therapies targeting areas of serious unmet need, including neutrophil-mediated inflammatory diseases and rare pulmonary disorders. Insmed is also advancing an early-stage research engine encompassing a wide range of technologies and modalities, including artificial intelligence-driven protein engineering, gene therapy, and protein manufacturing. Insmed is headquartered in Bridgewater, New Jersey, with additional offices and research locations throughout the United States, Europe, and Japan. Visit www.insmed.com to learn more.

Contact:

Investors:

Bryan Dunn
Executive Director, Investor Relations
Insmed
(646) 812-4030
bryan.dunn@insmed.com 

Eleanor Barisser
Associate Director, Investor Relations
Insmed
(718) 594-5332
eleanor.barisser@insmed.com 

Media:

Mandy Fahey
Executive Director, Corporate Communications
Insmed
(732) 718-3621
amanda.fahey@insmed.com

 

View original content to download multimedia:https://www.prnewswire.com/news-releases/insmed-to-host-investor-call-to-discuss-topline-results-from-phase-3-aspen-study-of-brensocatib-in-patients-with-bronchiectasis-302156113.html

SOURCE Insmed Incorporated

FAQ

When is Insmed hosting the investor call for the ASPEN study results?

Insmed is hosting the investor call on May 28, 2024, at 8:00 am ET.

What is the ASPEN study related to?

The ASPEN study assesses the efficacy, safety, and tolerability of brensocatib in patients with non-cystic fibrosis bronchiectasis.

How can I access the Insmed conference call?

The conference call can be accessed by dialing (800) 715-9871 (U.S.) or (646) 307-1963 (international) and referencing access code 1245105. It will also be webcast on the company's website.

When will the topline results of the ASPEN study be released?

The topline results will be released at approximately 6:30 am ET on May 28, 2024.

What is the stock symbol for Insmed?

The stock symbol for Insmed is INSM.

Until when will the replay of the investor call be available?

The replay will be available until June 27, 2024.